Welcome to our dedicated page for ESTABLISHMENT LABS HOLDINGS SEC filings (Ticker: ESTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ESTABLISHMENT LABS HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ESTABLISHMENT LABS HOLDINGS's regulatory disclosures and financial reporting.
Establishment Labs Holdings Inc. ownership table shows 1,578,119 common shares beneficially owned, representing 5.38% of the class as reported. The filing lists voting and dispositive powers across affiliated filers led by Brown Advisory Inc., with details of sole and shared voting/dispositive counts.
The schedule states the shares are held by investment companies and managed accounts of Brown Advisory subsidiaries and that Brown Advisory Inc. filed on behalf of those subsidiaries pursuant to the cited parent/subsidiary classification.
ESTABLISHMENT LABS HOLDINGS INC. director Juan Jose Chacon Quiros reported open-market sales of common shares executed on May 6, 2026 through entity Sariel Group Ltd, which holds the shares. The filing shows a total of 105,000 shares sold in two tranches under a pre-established Rule 10b5-1 trading plan, concluding that plan after all its shares were sold. Following these transactions, he continues to hold 45,193 common shares directly and 927,504 common shares indirectly through Sariel Group Ltd.
Establishment Labs Holdings Inc. reported first-quarter 2026 results showing strong growth but continued losses. Revenue rose to $59.9 million, up from $41.4 million a year earlier, driven by broader sales of Motiva Implants, including the United States.
Gross profit increased to $42.3 million, while the operating loss narrowed to $6.5 million and net loss improved to $13.4 million, or $0.45 per share. Cash and cash equivalents were $68.1 million, with net cash used in operating activities reduced to $4.3 million from $20.7 million. The balance sheet shows total assets of $351.0 million and shareholders’ equity of $14.8 million, alongside $246.4 million of Oaktree term debt and related obligations.
ESTABLISHMENT LABS HOLDINGS INC. had 60,000 Common Shares sold in an open-market transaction on May 6, 2026, by investment entities associated with JW Asset Management. The sale occurred at an average price of $75.625 per share and was executed indirectly through JW Partners, LP and JW Opportunities Fund, LLC.
After this sale, the reporting group collectively held 3,001,694 Common Shares indirectly. JW Asset Management, LLC, JW GP, LLC and Jason G. Wild each disclaim beneficial ownership of these securities except to the extent of any indirect pecuniary interest.
Establishment Labs Holdings Inc. reported strong first-quarter 2026 results with revenue of $59.9 million, up 44.7% from the same period in 2025, driven by Motiva sales and minimally invasive products. Gross margin improved to 70.7%, and the company delivered its third consecutive quarter of positive adjusted EBITDA.
Net loss narrowed to $13.4 million from $20.7 million a year earlier, while cash used in the quarter fell to $7.5 million and cash on hand was $68.1 million as of March 31, 2026. Management raised full-year 2026 revenue guidance to a range of $266.5 million to $268.5 million and now expects the minimally invasive business to exceed $35 million, with positive adjusted EBITDA every quarter and free cash flow positivity in the second half of 2026.
ESTABLISHMENT LABS HOLDINGS INC. director Juan Jose Chacon Quiros reported open-market sales totaling 75,000 Common Shares, executed indirectly through Sariel Group Ltd, an entity in which he has a pecuniary interest and over whose shares he has voting and dispositive power.
The sales occurred on May 1 and May 4, 2026 at weighted average prices between about $70 and $71 per share, under a Rule 10b5-1 trading plan. Following these transactions, Sariel Group Ltd holds 1,032,504 Common Shares indirectly attributed to him, and he also holds 45,193 Common Shares directly.
Establishment Labs Holdings Inc. entered into an amended credit agreement with Oaktree-affiliated lenders providing term loans of up to $300,000,000. The facility includes a $265,000,000 Tranche E funded at closing and a Tranche F of up to $35,000,000 available upon mutual consent.
About $259,000,000 from Tranche E will repay all obligations under the prior credit agreement and related costs, with remaining proceeds for working capital and general corporate purposes. The term loans bear interest at 8.75% per annum with partial payment-in-kind options in the first year, mature on April 30, 2031, carry a 1% original issue discount and a 1% exit fee on repayments, and are subject to prepayment premiums in the first three years.
ESTABLISHMENT LABS HOLDINGS INC. director Juan Jose Chacon Quiros reported indirect open-market sales totaling 75,000 common shares over April 23–27. The trades, executed at prices in the mid‑$60s per share, were carried out under a disclosed Rule 10b5-1 trading plan.
The shares were sold by Sariel Group Ltd., over which Chacon Quiros has voting and dispositive power, while disclaiming beneficial ownership beyond his pecuniary interest. After these sales, indirect holdings stood at 1,107,504 common shares, and a separate direct position was 45,193 common shares as of April 23.
Establishment Labs Holdings Inc. director-related entity Sariel Group Ltd sold 37,500 Common Shares of ESTA on April 14, 2026 in an open‑market transaction at a weighted average price of $65.228 per share, within a range of $65.00 to $65.60, under a pre‑arranged Rule 10b5-1 trading plan.
Following the sale, Sariel Group Ltd held 1,182,504 Common Shares indirectly attributable to director Juan Jose Chacon Quiros, while he also held 45,193 Common Shares directly. He disclaims beneficial ownership of Sariel Group Ltd’s shares except to the extent of his pecuniary interest.
Establishment Labs Holdings Inc. will hold its 2026 annual shareholder meeting virtually on May 22, 2026 at 1:00 pm Eastern Time. Shareholders will vote on electing six directors to one-year terms ending in 2027, an advisory “say‑on‑pay” approval of named executive officer compensation, and ratification of CBIZ CPAs P.C. as independent auditor for 2026.
The company reports 2025 revenue of $211.1 million, up 27.2% from 2024, with net loss narrowing to $51.1 million from $84.6 million and year‑end cash of $75.6 million. New CEO Filippo “Peter” Caldini’s pay mix emphasizes stock options, restricted stock units and an annual bonus tied to financial and strategic goals, reflecting a performance‑based compensation design.